237 related articles for article (PubMed ID: 22316374)
21. Ultrastructural change due to acquired cisplatin resistance in human bladder cancer cells.
Yoon SJ; Park I; Kwak C; Lee E
Oncol Rep; 2003; 10(5):1363-7. PubMed ID: 12883708
[TBL] [Abstract][Full Text] [Related]
22. [Molecular bases of platinum-resistance in testicular cancer].
Germà-Lluch JR; Piulats JM
Arch Esp Urol; 2013 Jun; 66(5):524-35. PubMed ID: 23793770
[TBL] [Abstract][Full Text] [Related]
23. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.
Zuiverloon TC; Theodorescu D
Pharmacogenomics; 2017 Aug; 18(12):1167-1178. PubMed ID: 28745580
[TBL] [Abstract][Full Text] [Related]
27. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
28. Inherent sensitivity and induced resistance to chemotherapeutic drugs and irradiation in human cancer cell lines: relationship to mutation frequencies.
Parris CN; Walker MC; Masters JR; Arlett CF
Cancer Res; 1990 Dec; 50(23):7513-8. PubMed ID: 2253200
[TBL] [Abstract][Full Text] [Related]
29. Update on chemotherapy for advanced bladder cancer.
Rosenberg JE; Carroll PR; Small EJ
J Urol; 2005 Jul; 174(1):14-20. PubMed ID: 15947569
[TBL] [Abstract][Full Text] [Related]
30. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
31. The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.
Woolbright BL; Choudhary D; Mikhalyuk A; Trammel C; Shanmugam S; Abbott E; Pilbeam CC; Taylor JA
Mol Cancer Ther; 2018 Sep; 17(9):2004-2012. PubMed ID: 29907593
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy for advanced bladder cancer.
Roth BJ
Semin Oncol; 1996 Oct; 23(5):633-44. PubMed ID: 8893874
[TBL] [Abstract][Full Text] [Related]
33. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
[TBL] [Abstract][Full Text] [Related]
34. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer.
Racioppi M; D'Agostino D; Totaro A; Pinto F; Sacco E; D'Addessi A; Marangi F; Palermo G; Bassi PF
Urol Int; 2012; 88(3):249-58. PubMed ID: 22354060
[TBL] [Abstract][Full Text] [Related]
35. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal.
Gosland M; Lum B; Schimmelpfennig J; Baker J; Doukas M
Pharmacotherapy; 1996; 16(1):16-39. PubMed ID: 8700790
[TBL] [Abstract][Full Text] [Related]
36. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms.
Li F; Zheng Z; Chen W; Li D; Zhang H; Zhu Y; Mo Q; Zhao X; Fan Q; Deng F; Han C; Tan W
Drug Resist Updat; 2023 May; 68():100938. PubMed ID: 36774746
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of cisplatin resistance.
Galluzzi L; Senovilla L; Vitale I; Michels J; Martins I; Kepp O; Castedo M; Kroemer G
Oncogene; 2012 Apr; 31(15):1869-83. PubMed ID: 21892204
[TBL] [Abstract][Full Text] [Related]
38. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaboration.
Scher HI
J Urol; 1995 Nov; 154(5):1970. PubMed ID: 7563394
[No Abstract] [Full Text] [Related]
39. Mechanism of cisplatin resistance in human urothelial carcinoma cells.
Yu HM; Wang TC
Food Chem Toxicol; 2012 May; 50(5):1226-37. PubMed ID: 22326969
[TBL] [Abstract][Full Text] [Related]
40. Dicoumarol enhances doxorubicin-induced cytotoxicity in p53 wild-type urothelial cancer cells through p38 activation.
Matsui Y; Watanabe J; Ding S; Nishizawa K; Kajita Y; Ichioka K; Saito R; Kobayashi T; Ogawa O; Nishiyama H
BJU Int; 2010 Feb; 105(4):558-64. PubMed ID: 19583730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]